Expectations trend
FY2028 · fiscal year ending 2028-04-30 · fmp
$-1.75 → $-1.75 · observed estimates
HEARTSCIENCES INC (HSCS)
NASDAQHealth CareMedical - DevicesSnapshot 2026-11-04
$2.67-13.87%
Close 2026-11-05 · 1-day change
NASDAQHealth CareMedical - DevicesSnapshot 2026-11-04
The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.
Next-FY EPS estimate change · 30 days
Matching fiscal periods, usable estimates and at least one analyst are required.
One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.
The calculation requires same-period, same-provider snapshots, positive EPS, at least one analyst and a baseline within three days of the requested lookback.
The EPS and P/E reference is not available for HSCS yet.
| Measure / period | Management expectations | Analyst expectations |
|---|
Management figures unavailable.
Current consensus figures unavailable.
5 published thesis conditions, with dated milestones shown separately.
| Key Factor | Why It Matters | Current Status | Break Condition | Latest Evidence |
|---|---|---|---|---|
Increase revenue above $14,700 by 2026-Q3 | A primary condition in HEARTSCIENCES INC's published investment case. The stated target is >= $14,700 revenue by 2026-Q3. | Intact | revenue falls below $7,350 (half of peak $14,700) by 2026-Q3 | Revenue: $2,100 FY2027-Q1; GAAP. Published target: >= $14,700 revenue by 2026-Q3. The stored target says 2026-Q3; this source reports FY2027-Q1. Fiscal/calendar alignment needs review. Sep 14, 20262,100 USD · source valueLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Compare these dated observations with the operating requirements above
FY2028 · fiscal year ending 2028-04-30 · fmp
$-1.75 → $-1.75 · observed estimates
The evidence, the remaining questions, and what comes next
No recovery evidence is reported in the available driver assessments.
Observed price history; separate from operating scenarios
The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.
This is a speculative, loss-making business with elevated risk, weak recent performance, and volatile management. The thesis is on watch: stated operating and product milestones offer some progress, but the evidence does not yet show a consistent financial turnaround.
The snapshot gives no valuation multiple or peer comparison, so it is not possible to describe HSCS as cheap, fair, or expensive. It also provides no clear account of the market’s expectations; the low fragility tier only indicates that no listed fragility checks were triggered.
Near term, earnings execution is a concern: HSCS recently missed earnings, has a run of consecutive misses, and the snapshot assigns a 51% miss probability for the next report. Over the multi-year view, Fortitude reported mining and revenue activity, while MyoVista reached full commercial launch and received FDA clearance for its wavECG device without the AI algorithm; execution and financial impact remain uncertain.
A key swing factor is whether the merger with Fortitude closes in Q4 2026, subject to shareholder approval and customary conditions, and whether the mining platform continues to scale. The other major test is whether MyoVista’s AI-enabled ECG plans gain traction; a guidance cut would add a near-term negative, while continued strength from healthcare sector leaders could support the sector backdrop.
The multi-year view remains a watch case, not a demonstrated turnaround: merger completion and delivery across mining and ECG matter, while weak results and repeated earnings misses remain material risks. Not investment advice.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Stabilize leadership after CEO and COO changes | Management is addressing leadership changes to stabilize operations. | Intact | additional CEO or COO departures before 2026-Q4 | Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Date unavailableLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Reduce operating losses from -$1.9 million in 2026-Q3 | A primary condition in HEARTSCIENCES INC's published investment case. The stated target is operating loss less negative than -$1.9 million by 2026-Q3. | Intact | operating loss worsens beyond -$2.5 million by 2026-Q3 | Operating income: $-2.939M FY2027-Q1; GAAP. Published target: operating loss less negative than -$1.9 million by 2026-Q3. The stored target says 2026-Q3; this source reports FY2027-Q1. Fiscal/calendar alignment needs review. Sep 14, 2026-2,939,090 USD · source valueLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Maintain financing at or above $3.6 million secured in 2026-Q2 | HeartSciences is actively improving its finances with $3.6 million secured in new financing. | Intact | financing falls below $2 million or no new financing by 2026-Q3 | Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Date unavailableLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Complete merger agreements to expand market presence | A supporting condition in HEARTSCIENCES INC's published investment case. The stated target is At least one material merger completed by 2026-Q4. | Improving | no material merger completed by 2026-Q4 | Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Date unavailableLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.
$0.00B → $0.00B · observed estimates
One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.
| Snapshot | EPS | Revenue | EPS / revenue analysts |
|---|---|---|---|
| 2026-10-22 | $-1.75 | $3,150,000 | 1 / 1 |
| 2026-10-23 | $-1.75 | $3,150,000 | 1 / 1 |
| 2026-10-24 | $-1.75 | $3,150,000 | 1 / 1 |
| 2026-10-25 | $-1.75 | $3,150,000 | 1 / 1 |
| 2026-10-26 | $-1.75 | $3,150,000 | 1 / 1 |
| 2026-10-27 | $-1.75 | $3,150,000 | 1 / 1 |
| 2026-10-28 | $-1.75 | $3,150,000 | 1 / 1 |
| 2026-10-29 | $-1.75 | $3,150,000 | 1 / 1 |
| 2026-10-30 | $-1.75 | $3,150,000 | 1 / 1 |
| 2026-10-31 | $-1.75 | $3,150,000 | 1 / 1 |
| 2026-11-01 | $-1.75 | $3,150,000 | 1 / 1 |
| 2026-11-02 | $-1.75 | $3,150,000 | 1 / 1 |
| 2026-11-03 | $-1.75 | $3,150,000 | 1 / 1 |
| 2026-11-04 | $-1.75 | $3,150,000 | 1 / 1 |
Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.
Latest: 1 Buy / Strong Buy · 0 Hold · 0 Sell / Strong Sell
Recent actions · Oct 6–Nov 4 · 0 recorded
Individual price-target observations are unavailable.
0 raises · 0 cuts · 0 unchanged · 0 without a comparable prior
Oct 6, 2026–Nov 4, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.
Dec 21, 2026
Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.
Review earnings5 of 5 published conditions remain under pressure or need verification. The next results need to address those conditions.
The dated weekly assessment and its assumptions are available in Read detailed Outlook.